The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Three keynote speakers have been chosen for the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025). The speakers include Sagar
This issue features a story on myeloMATCH, an in-depth interview with Pia Raanani, MD, PhD, head of the Institute of Hematology at the
In elderly patients with acute myeloid leukemia (AML), allogeneic hematopoietic cell transplantation (HCT) improves leukemia-free survival (LFS) according to a prospective randomized study.
Pia Raanani, MD, head of the Institute of Hematology at the Davidoff Cancer Center at the Rabin Medical Center in Israel, shared her
Guillermo Garcia-Manero MD, of the University of Texas MD Anderson Cancer Center, discusses long-term data from the COMMANDS trial, highlighting the use of
Do you have a question about the treatment or management of leukemias? Submit your question in our new forum in the SOHO mobile
Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, has been approved in the United States in combination with bendamustine and rituximab for the treatment
An Investigational New Drug (IND) application for KF1601, a chronic myeloid leukemia (CML) treatment was submitted to and approved by the Korea Ministry
The US Food and Drug Administration (FDA) has granted fast track designation to LYT-200 for the treatment of acute myeloid leukemia (AML). LYT-200
FT596, a CD19-directed chimeric antigen receptor (CAR) natural killer (NK) cell therapy, was well tolerated in patients with relapsed or refractory B-cell lymphoma
